8-K current report · filed Nov 9, 2026

Trevi Therapeutics, Inc. (TRVI) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1TRVI overview

Short answer

Trevi Therapeutics, Inc. (TRVI) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.

Trevi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1, relevant for assessing Trevi’s operating performance and financial position

Item EX-99.1 · Exhibit EX-99.1

  • Cash, equivalents and marketable securities $299.4M, supporting runway into 2030 and key Haduvio clinical milestones
  • Phase 3 OCEAN-2 initiated for IPF cough, with topline results expected in second half 2027
  • FDA alignment supports Phase 2 non-IPF ILD trial launch in Q1 2027, testing 54 mg BID and 27 mg BID
  • Q3 net loss $21.5M versus $11.8M, with R&D rising to $19.1M from $10.1M as clinical spending accelerates
  • USPTO Notice of Allowance could provide patent protection through 2041 for hepatically impaired non-IPF ILD patients

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Trevi Therapeutics, Inc. 8-K filings

Get the next TRVI 8-K as it lands

Follow TRVI for push alerts, or ask the research agent what this filing means.